PTC Inc. (NASDAQ:PTC) is among the most profitable software stocks to buy now. On February 9, TheFly reported that BofA ...

HONOLULU, HI, UNITED STATES, January 29, 2026 /EINPresswire.com/ -- PTC, a global non profit advancing digital ...

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna.  | Late Thursday, PTC revealed that ...

Enables faster, more collaborative product execution with a cloud-based PLM solution built to support future growth BOSTON, ...

Q4 2025 Management View CEO Matthew Klein highlighted 2025 as a year of “many significant successes,” citing the initial global approvals and launch of Sephience for PKU as the main highlight. Klein ...

Honorees recognized at PTC’s largest annual conference in its 48 year history Each recipient is contributing in ...

PTC Inc. closed 30.32% short of its 52-week high of $219.69, which the company achieved on July 31st.

PTC Therapeutics, Inc. PTCT closed lower on Thursday following the company’s decision to withdraw its New Drug Application for Translarna after receiving feedback from the U.S. Food and Drug ...

PTC ended the year with $1.95 billion in cash, cash equivalents and marketable securities, up from $1.14 billion at the end of 2024.

PTC Therapeutics announced it will withdraw the ataluren NDA for nmDMD, citing FDA concerns regarding the evidence of the agent's effectiveness.